Trial · NCT03463265
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: Nab-sirolimus in Patients With Recurrent High Grade Glioma | 7 | |
| Overall Study | STARTED | Arm A: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma | 6 | |
| Overall Study | STARTED | Arm A: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma | 9 | |
| Overall Study | STARTED | Arm A: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma | 4 | |
| Overall Study | STARTED | ArmA: Nab-sirolimus + Marizomib (MRZ) in Patients With Recurrent High Grade Glioma | 10 | |
| Overall Study | STARTED | Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma | 26 | |
| Overall Study | COMPLETED | Arm A: Nab-sirolimus in Patients With Recurrent High Grade Glioma | 7 | |
| Overall Study | COMPLETED | Arm A: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma | 6 | |
| Overall Study | COMPLETED | Arm A: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma | 9 | |
| Overall Study | COMPLETED | Arm A: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma | 4 | |
| Overall Study | COMPLETED | ArmA: Nab-sirolimus + Marizomib (MRZ) in Patients With Recurrent High Grade Glioma | 10 | |
| Overall Study | COMPLETED | Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma | 26 | |
| Overall Study | NOT COMPLETED | Arm A: Nab-sirolimus in Patients With Recurrent High Grade Glioma | 0 | |
| Overall Study | NOT COMPLETED | Arm A: Nab-sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma | 0 | |
| Overall Study | NOT COMPLETED | Arm A: Nab-sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma | 0 | |
| Overall Study | NOT COMPLETED | Arm A: Nab-sirolimus + Lomustine in Patients With Recurrent High Grade Glioma | 0 | |
| Overall Study | NOT COMPLETED | ArmA: Nab-sirolimus + Marizomib (MRZ) in Patients With Recurrent High Grade Glioma | 0 | |
| Overall Study | NOT COMPLETED | Arm B: Nab-sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03463265/flow